Omazilumab - Treatment for Allergic Reactions and Autoimmune Diseases

Image credit: journals.sagepub.com

When did omalizumab become a drug?

In 1987 Tanox filed its first patent application on the anti-IgE drug candidates. It took until 2003, in the United States until omalizumab was approved, in Europe until 2005 for moderate to severe persistent asthma, severe chronic rhinosinusitis with nasal polyps. In February 2024, the FDA approved it also to treat severe food allergy.

What is the mechanism of action of omalizumab?

The mechanism of action of omalizumab differs for allergic asthma and chronic urticaria. The direct action of omalizumab involves selective binding to the C-epsilon-3 locus, the domain at which IgE binds to Fc-epsilon-RI.

When does omalizumab cause anaphylaxis?

Anaphylaxis has occurred as early as after the first dose of omalizumab but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after omalizumab administration.

Is omalizumab a biological medicine?

Omalizumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing; record the brand name and batch number after each administration. For choice of therapy, see Asthma, acute and Asthma, chronic.

How do I identify appropriate patients for omalizumab therapy?

Identify appropriate patients for omalizumab therapy based on indications, such as moderate-to-severe asthma or chronic urticaria. Screen patients thoroughly for eligibility, including total serum IgE levels, potential contraindications, and medical history, before initiating omalizumab treatment.

Does omalizumab increase cancer risk?

There is no evidence that omalizumab increases your risk of developing cancers. Studies using omalizumab have observed patients for up to one year after treatment and therefore long-term side effects are unknown. Can omalizumab increase the risk of having blood clots or a stroke?

Does omalizumab increase thrombogenic activity?

Polyestradiol phosphate may increase the thrombogenic activities of Omalizumab. The serum concentration of Pozelimab can be decreased when it is combined with Omalizumab. Quinestrol may increase the thrombogenic activities of Omalizumab. The risk or severity of adverse effects can be increased when Omalizumab is combined with Ramucirumab.

What Is Omazilumab (fictional)

1. https://en.wikipedia.org/wiki/Omalizumab
2. https://bnf.nice.org.uk/drugs/omalizumab/
3. https://www.drugs.com/omalizumab.html
4. https://www.royaldevon.nhs.uk/media/c0wf4don/patient-information-leaflet-omalizumab-xolair-rde-20-207-001.pdf
5. https://www.ncbi.nlm.nih.gov/books/NBK545183/
6. https://go.drugbank.com/drugs/DB00043
7. https://www.medicine.com/drug/omalizumab/hcp
8. https://www.nejm.org/doi/full/10.1056/NEJMoa1215372
9. https://medlineplus.gov/druginfo/meds/a603031.html

Omazilumab (fictional) Information

1. https://www.bad.org.uk/pils/omalizumab/
2. https://cdn.bad.org.uk/uploads/2021/12/29200255/Omazlizumab-Update-February-2018-Lay-review-June-2017-revised2.pdf
3. https://www.skinhealthinfo.org.uk/wp-content/uploads/2018/11/Omalizumab-PIL-March-2023.pdf
4. https://www.nice.org.uk/guidance/TA278